- Home
- CZNC vs ZURA Comparison
CZNC vs ZURA Comparison
Compare CZNC & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | ZURA |
|---|---|---|
| Founded | 1864 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.7M | 435.0M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | CZNC | ZURA |
|---|---|---|
| Price | $21.52 | $6.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $23.50 | $11.78 |
| AVG Volume (30 Days) | 40.5K | ★ 457.9K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.17% | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.02 | $0.99 |
| 52 Week High | $24.12 | $7.25 |
Technical Indicators
Market Signals| Indicator | CZNC | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 35.58 | 47.45 |
| Support Level | $19.82 | $5.62 |
| Resistance Level | $22.45 | $6.90 |
| Average True Range (ATR) | 0.59 | 0.51 |
| MACD | -0.22 | -0.06 |
| Stochastic Oscillator | 9.13 | 4.21 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.